← Leaderboards
Susanne Heynen-Genel
Sanford Burnham Prebys Medical Discovery Institute
$2,110,636
Attributed
$4,221,272
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,221,272 · 4
By mechanism
R01$1,905,554 · 1
R61$1,262,407 · 1
R33$596,061 · 1
R56$457,250 · 1
Top collaborators
- Cosimo Commisso3 shared
- Andrew Jon Haak3 shared
- Daniel J. Tschumperlin1 shared
Most similar at Sanford Burnham Prebys Medical Discovery Institute
Same institution · by research overlap
- Andrew Jon Haak$2,107,274
- Cosimo Commisso$11,152,767
- Shea Grenier Davis$40,810
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsNovel TherapeuticsPlayPathway InteractionsIn VivoHigh Throughput ScreeningMouse ModelScreeningScaffoldInhibitorUnited StatesTherapeutically EffectiveAnalogCessation Of LifeSmall MoleculeSmall Molecule InhibitorGrantStructure-Activity RelationshipDiversity LibraryPharmaceutical PreparationsTherapeutic AgentsHomeostasisCell TypeIdiopathic Pulmonary Fibrosis
Grant awards (7)
Discovery of Novel Inhibitors Targeting trans-Golgi Network Acidification in Pancreatic Cancer$645,331
R01 · FY2025 · CA
Discovery of Novel Inhibitors Targeting trans-Golgi Network Acidification in Pancreatic Cancer$612,825
R01 · FY2024 · CA
Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis$596,061
R33 · FY2024 · HL · contact PI
Discovery of Novel Inhibitors Targeting trans-Golgi Network Acidification in Pancreatic Cancer$647,398
R01 · FY2023 · CA
Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis$618,908
R61 · FY2023 · HL · contact PI
Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis$643,499
R61 · FY2022 · HL · contact PI
Screening for fibroblast-selective inhibitors of YAP/TAZ$457,250
R56 · FY2018 · AG